[18F]F-DOPA Imaging in Patients with Autonomic Failure

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
Autonomic FailurePure Autonomic FailureParkinson DiseaseMultiple System AtrophyDementia with Lewy Bodies
Interventions
DRUG

[18F]FDOPA

Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of \[18F\]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.

DRUG

Carbidopa 200mg oral dose

30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.

DRUG

Entacapone 400mg oral dose

30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.

Trial Locations (1)

37212

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Daniel Claassen

OTHER

NCT04246437 - [18F]F-DOPA Imaging in Patients with Autonomic Failure | Biotech Hunter | Biotech Hunter